Century Therapeutics, Inc. Earnings Per Share (Basic)
Century Therapeutics, Inc. (IPSC) reported Earnings Per Share (Basic) of -$0.17 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Century Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.17.
- Century Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.11, a 112.36% decline year-over-year.
- Century Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.22.
- Century Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.40.
- Century Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.14.
- Century Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.61.
- Century Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.30.
- Century Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.27.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.17 10-Q · filed 2026-08-12 | -$0.28 10-Q · filed 2026-08-12 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.11 10-Q · filed 2026-05-13 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.95 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.14 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.40 10-Q · filed 2025-11-13 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.11 10-Q · filed 2025-11-13 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.38 10-Q · filed 2026-08-12 | $0.51 10-Q · filed 2026-08-12 | $0.09 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | $0.89 10-Q · filed 2026-05-13 | $0.47 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.11 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2024-12-31 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.61 10-K · filed 2026-03-12 |
| 2024-09-30 | -$0.37 10-Q · filed 2025-11-13 | -$0.75 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.18 10-Q · filed 2025-11-13 | -$1.80 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-06-30 | -$0.38 10-Q · filed 2025-08-14 | -$0.82 10-Q · filed 2025-08-14 | -$1.45 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.99 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2024-03-31 | -$0.45 10-Q · filed 2025-05-15 | -$1.10 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.65 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$2.22 derived: net income ÷ weighted average shares · filed 2025-11-13 |
| 2023-12-31 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$1.21 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$1.77 derived: net income ÷ weighted average shares · filed 2025-03-19 | -$2.30 10-K · filed 2025-03-19 |
| 2023-09-30 | -$0.55 10-Q · filed 2024-11-05 | -$1.11 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.65 10-Q · filed 2024-11-05 | -$2.19 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-06-30 | -$0.56 10-Q · filed 2024-08-08 | -$1.10 10-Q · filed 2024-08-08 | -$1.64 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.17 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-03-31 | -$0.53 10-Q · filed 2024-05-09 | -$1.08 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.61 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.14 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2022-12-31 | -$0.54 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.07 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.61 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$2.27 10-K · filed 2024-03-14 |
| 2022-09-30 | -$0.53 10-Q · filed 2023-11-09 | -$1.07 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.72 10-Q · filed 2023-11-09 | -$2.24 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.54 10-Q · filed 2023-08-09 | -$1.19 10-Q · filed 2023-08-09 | -$1.71 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.19 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-03-31 | -$0.66 10-Q · filed 2023-05-11 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.65 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.57 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2021-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$0.99 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.91 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$2.96 10-K · filed 2023-03-16 |
| 2021-09-30 | -$0.48 10-Q · filed 2022-11-10 | -$1.48 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$2.72 10-Q · filed 2022-11-10 | -$4.07 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$1.93 10-Q · filed 2022-08-11 | -$4.26 10-Q · filed 2022-08-11 | -$6.30 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$8.10 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-03-31 | -$2.39 10-Q · filed 2022-05-16 | -$4.47 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$6.22 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$8.27 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2020-12-31 | -$2.08 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$3.82 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$5.87 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$7.16 10-K · filed 2022-03-17 |
| 2020-09-30 | -$1.75 10-Q · filed 2021-11-10 | -$3.79 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$5.08 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$2.05 10-Q · filed 2021-08-12 | -$3.34 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |